{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:49:48Z","timestamp":1791614988328,"version":"4.3.4"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["LMS25H050004"],"award-info":[{"award-number":["LMS25H050004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001705"],"award-info":[{"award-number":["82001705"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy and safety of finerenone, with or without combination therapy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) or renin-angiotensin system inhibitors (RASi), in Chinese patients with non-diabetic chronic kidney disease (non-diabetic CKD) at different follow-up time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with non-diabetic CKD who received finerenone treatment from March 2023 to August 2025 were retrospectively enrolled. According to the treatment regimens, patients were divided into four groups: finerenone monotherapy group (without SGLT2i or RASi), finerenone + SGLT2i group, finerenone + RASi group, and finerenone + SGLT2i + RASi group. The main evaluated indicators included urine albumin-to-creatinine ratio (UACR), urine protein-to-creatinine ratio (UPCR), serum creatinine (Scr), estimated glomerular filtration rate (eGFR), and serum potassium (K+) levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 483 patients were enrolled in this study, including 229 males (47.41%); baseline UACR was 520.1 (interquartile range [IQR], 259.2\u2013993.9) mg\/g. After receiving finerenone treatment for 18 months, the UACR decreased by 69.18%. During the study period, the change in eGFR remained stable, with only 2.48% of patients experiencing an eGFR decline &amp;gt;30%. Hyperkalemia occurred in only 6 patients (1.24%), indicating a good safety profile during the medication period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Finerenone can effectively reduce proteinuria in patients with non-diabetic CKD. Dual or triple combination therapy demonstrated more pronounced effects, with an overall favorable safety profile. Nevertheless, careful monitoring of short-term changes in eGFR and serum K+ levels remains essential during finerenone therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag094","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:42:55Z","timestamp":1775821375000},"page":"1206-1213","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0140-2590","authenticated-orcid":false,"given":"Yanli","family":"Fang","sequence":"first","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Shao","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Lin","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Xu","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shang","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Chen","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Chen","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqiu","family":"Lv","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianna","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3638-527X","authenticated-orcid":false,"given":"Huidi","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Clinical College, Wenzhou Medical University , Wenzhou ,","place":["China"]},{"name":"Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University , Wenzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026101002215710700_aajag094-B1","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/s2214-109x(24)00050-0","article-title":"The major global burden of chronic kidney disease","volume":"12","author":"Jadoul","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026101002215710700_aajag094-B2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026101002215710700_aajag094-B3","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/ndt\/gfad112","article-title":"SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA","volume":"38","author":"Mark","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002215710700_aajag094-B4","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101002215710700_aajag094-B5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002215710700_aajag094-B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol."},{"key":"2026101002215710700_aajag094-B7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1159\/000371497","article-title":"Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy","volume":"40","author":"Ruilope","year":"2014","journal-title":"Am J Nephrol"},{"key":"2026101002215710700_aajag094-B8","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2025.2545939","article-title":"Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD","volume":"47","author":"Li","year":"2025","journal-title":"Ren Fail"},{"key":"2026101002215710700_aajag094-B9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"key":"2026101002215710700_aajag094-B10","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70078","article-title":"Early efficacy and safety of finerenone on type 2 diabetes-related chronic kidney disease: a real-world observational study in China","volume":"41","author":"Lin","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"2026101002215710700_aajag094-B11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/ndt\/gfab336","article-title":"Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002215710700_aajag094-B12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026101002215710700_aajag094-B13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.kint.2025.03.018","article-title":"Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis","volume":"108","author":"Navaneethan","year":"2025","journal-title":"Kidney Int"},{"key":"2026101002215710700_aajag094-B14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int"},{"key":"2026101002215710700_aajag094-B15","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1681\/asn.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026101002215710700_aajag094-B16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/circulationaha.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026101002215710700_aajag094-B17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2215\/cjn.0000000000000205","article-title":"Influence of SGLT2i and RAASi and their combination on risk of hyperkalemia in DKD: a network meta-analysis","volume":"18","author":"Luo","year":"2023","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1206\/70253731\/aajag094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/6\/1206\/70253731\/aajag094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:22:05Z","timestamp":1791613325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/6\/1206\/8743970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag094","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]}}}